Together, these results strongly suggest that blocking CDK4 activity leads to increased expression of the differentiation factor BMP4, resulting in decreased CD44+/CD24− BCSC numbers, and further leading to inhibition of breast cancer stemness. Here, CD44 is linked to breast carcinoma.